CollPlant Biotechnologies Ltd (CLGN) stock
CLGNNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31Also trades as OPHI
$3.96+0.06 (+1.54%)
Close on Nov 11, 2026Market cap –P/E –Yield –
CollPlant Biotechnologies EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -$9.40. The highest annual figure on record is $22.70 in fiscal 2017.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.40 | – |
| FY2024 | Dec 31, 2024 | -$14.50 | – |
| FY2023 | Dec 31, 2023 | -$6.20 | – |
| FY2022 | Dec 31, 2022 | -$15.30 | -7750.0% |
| FY2021 | Dec 31, 2021 | $0.20 | – |
| FY2020 | Dec 31, 2020 | -$8.40 | – |
| FY2019 | Dec 31, 2019 | -$22.30 | -255.9% |
| FY2018 | Dec 31, 2018 | $14.30 | -37.0% |
| FY2017 | Dec 31, 2017 | $22.70 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | $2.80 | – |
| Q2 FY2024 | Jun 30, 2024 | $3.70 | – |
| Q2 FY2023 | Jun 30, 2023 | $4.90 | +81.5% |
| Q2 FY2022 | Jun 30, 2022 | -$3.90 | -208.3% |
| Q2 FY2021 | Jun 30, 2021 | -$3.00 | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.80 | – |
| Q2 FY2019 | Jun 30, 2019 | $2.70 | – |
| Q2 FY2018 | Jun 30, 2018 | $3.60 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?